- Immix gets FDA’s green light to expand trial for cancer combination therapy
July 24, 2019 8:37 am
- Global Malignant Mesothelioma Therapeutics Market 2019-2023 | 7% CAGR Projection Over the Next Five Years | Technavio
July 24, 2019 7:00 am
- Dassault Systèmes and the FDA Extend Collaboration to Inform Cardiovascular Device Review Process and Accelerate Access to New Treatments
July 24, 2019 7:00 am
- Global Malignant Mesothelioma Therapeutics Market, 7% CAGR Projection Over the Next Five Years
July 24, 2019 7:00 am
- Jubilant Cadista Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, Due to Out-of-Specification Dissolution Test Results July 24, 2019 3:44 am
- Bio-Rad to Report Second-Quarter 2019 Financial Results July 24, 2019 2:46 am
- Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region July 24, 2019 12:00 am
- Veristat Expands Operations into Taiwan to Support Growing Client Demand for Clinical Trial, Biostatistics and Programming Excellence in the Region July 24, 2019 12:00 am
- Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company July 23, 2019 10:15 pm
- Seattle Genetics Announces Proposed Public Offering of Common Stock July 23, 2019 10:09 pm
- Merck Announces Fourth-Quarter 2019 Dividend July 23, 2019 6:54 pm
- Global Musculoskeletal Disorders Drugs Market Report 2019 Featuring F. Hoffmann-La Roche, GlaxosmithKline, Pfizer, Abbott Laboratories, Daiichi Sankyo – ResearchAndMarkets.com July 23, 2019 5:54 pm
My Pharmaceutical
PCSK9is shown to lower improve cardiovascular outcomes, many rejected by their insurance plan
New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.
